Exogenous expression of human apoA-I enhances cardiac differentiation of pluripotent stem cells

Kwong-Man Ng1, Yee-Ki Lee, Wing-Hon Lai

  • 1Stem Cell & Regenerative Medicine Program, Research Centre of Heart, Brain, Hormone and Healthy Ageing, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.

Plos One
|May 19, 2011
PubMed

Insights

Apolipoprotein A1 (apoA-I) enhances embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) cardiac differentiation and maturation. This effect is mediated by the BMP4-SMAD signaling pathway, improving cardiomyocyte function.

Area of Science:

  • Stem cell biology
  • Cardiovascular research
  • Molecular cardiology

Background:

  • High-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (apoA-I) possess known cardioprotective effects.
  • The role of apoA-I in the cardiac differentiation of embryonic stem cells (ESCs) remains largely unexplored.

Purpose of the Study:

  • To investigate the effects of exogenous apoA-I expression on the cardiac differentiation and maturation of ESCs and human induced pluripotent stem cells (iPSCs).
  • To elucidate the underlying signaling pathways involved in apoA-I-mediated cardiac differentiation.

Main Methods:

  • Stable overexpression of human apoA-I cDNA in mouse ESCs and human iPSCs using lentivirus (LV)-mediated gene transfer.
  • Assessment of cardiac differentiation via quantification of beating embryoid bodies, flow cytometry for cardiomyocyte numbers, and analysis of cardiac marker gene expression.
  • Investigation of the BMP4-SMAD signaling pathway using BMP4 antagonists and co-application studies with recombinant apoA-I and BMP4.

Main Results:

  • LV-apoA-I transduction significantly increased the percentage of beating embryoid bodies and the number of cardiomyocytes derived from ESCs compared to controls.
  • ApoA-I overexpression led to enhanced expression of key cardiac markers (α-MHC, β-MHC, MLC2v) and improved calcium handling properties in derived cardiomyocytes.
  • The pro-cardiogenic effects of apoA-I were found to be mediated through the BMP4-SMAD signaling pathway, as demonstrated by the abolition of effects with noggin and synergistic effects with BMP4.

Conclusions:

  • Apolipoprotein A1 (apoA-I) significantly enhances cardiac differentiation and maturation of both ESCs and iPSCs.
  • The mechanism involves the activation of the BMP4-SMAD signaling pathway.
  • ApoA-I promotes improved functional properties, specifically calcium handling, in ESC-derived cardiomyocytes.